There is an unmet clinical need in predictive biomarkers and preventive therapies for metastatic progression in cancer. Circulating tumor cells (CTCs) isolated from standard blood draws have become important prognostic markers in cancer therapy. Phenomyx is building a revolutionary platform for the phenotypic screening of the metastatic potential of CTCs. By screening CTCs for aggressive invasion phenotypes we can provide sensitive multi-parameter biomarkers of metastatic potential. The company is designing its technology platform to provide a rapid screen for CTCs with the highest metastatic potential, identify target organs for metastases and enable discovery of small molecule inhibitors of the metastatic cascade. Phenomyx's platform technology will have direct impact on the 90% of cancer deaths due to metastatic disease progression.
- Salil Desai, PhD Founder & Chief Technology Officer